Eldorado Hotel & Spa Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2013
Here are the related meetings in 2020:
Cancer Epigenetics: New Mechanisms and Therapeutic Opportunities (J4)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Epigenetic Marks and Cancer Drugs (C8)
Organizer(s) Ali Shilatifard
March 20—25, 2013
Eldorado Hotel & Spa • Santa Fe, NM USA
Abstract Deadline: Nov 19, 2012
Late Abstract Deadline: Dec 21, 2012
Scholarship Deadline: Nov 19, 2012
Early Registration Deadline: Jan 22, 2013
Sponsored by AVEO Oncology, Celgene Corporation, Genentech, Inc. and H3 Biomedicine Inc.
Summary of Meeting:
To regulate the precise pattern of gene expression during development, eukaryotic cells have evolved to have multifaceted transcriptional machineries and chromatin states. The DNA within the eukaryotic nucleus is found in complex with histone proteins to form nucleosomes, the basic unit of chromatin. Detailed structural studies demonstrated that the N-terminal tails of each of the histones protrude outward beyond the gyres of DNA and can be posttranslationally modified. The modifications of histone tails could provide a landing pad for a diverse array of transcription factors, chromatin remodelers, and DNA-interacting proteins to regulate gene expression. Translocations and/or mutations in chromatin-modifying machineries that perturb the timing and/or pattern of gene expression can result in the pathogenesis of human diseases including cancer. Recent studies demonstrate that the misregulation of several of the histone-modifying enzymes can contribute to changes in the epigenetic state leading to disease development. Therefore, both the scientific and the pharmaceutical communities have concentrated on identifying the molecular function for many of the histone-modifying machineries and are in the process of developing small molecular inhibitors of their activities in the hope of their use for targeted therapeutics of cancer. This Keystone Symposia meeting on Epigenetic Marks and Cancer Drugs serves as a much-needed platform for bringing both the scientific and the pharmaceutical communities together to discuss recent advances in this very exciting area.
View Scholarships/Awards
To regulate the precise pattern of gene expression during development, eukaryotic cells have evolved to have multifaceted transcriptional machineries and chromatin states. The DNA within the eukaryotic nucleus is found in complex with histone proteins to form nucleosomes, the basic unit of chromatin. Detailed structural studies demonstrated that the N-terminal tails of each of the histones protrude outward beyond the gyres of DNA and can be posttranslationally modified. The modifications of histone tails could provide a landing pad for a diverse array of transcription factors, chromatin remodelers, and DNA-interacting proteins to regulate gene expression. Translocations and/or mutations in chromatin-modifying machineries that perturb the timing and/or pattern of gene expression can result in the pathogenesis of human diseases including cancer. Recent studies demonstrate that the misregulation of several of the histone-modifying enzymes can contribute to changes in the epigenetic state leading to disease development. Therefore, both the scientific and the pharmaceutical communities have concentrated on identifying the molecular function for many of the histone-modifying machineries and are in the process of developing small molecular inhibitors of their activities in the hope of their use for targeted therapeutics of cancer. This Keystone Symposia meeting on Epigenetic Marks and Cancer Drugs serves as a much-needed platform for bringing both the scientific and the pharmaceutical communities together to discuss recent advances in this very exciting area.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
WEDNESDAY, MARCH 20
THURSDAY, MARCH 21
FRIDAY, MARCH 22
SATURDAY, MARCH 23
SUNDAY, MARCH 24
MONDAY, MARCH 25
Conference Program Print | View meeting in 12 hr (am/pm) time
WEDNESDAY, MARCH 20
08:00—09:00
Welcome and Keynote Address
Stuart L. Schreiber,
HHMI/Harvard University, USA
Linking Genetic Features of Human Cancers and Histone-Modifying Enzymes for Future Cancer Therapies
Linking Genetic Features of Human Cancers and Histone-Modifying Enzymes for Future Cancer Therapies
09:00—11:00
Chromosomes, Chromatin and Transcription I
B. Franklin Pugh,
Pennsylvania State University, USA
Hemisomes and Nucleosomal Assymeetry across the Saccharomyces cerevisiae Genome
Hemisomes and Nucleosomal Assymeetry across the Saccharomyces cerevisiae Genome
Patrick Cramer,
Max Planck Institute for Biophysical Chemistry, Germany
New Insights into the Mechanisms of Transcription and its Regulation
New Insights into the Mechanisms of Transcription and its Regulation
Siavash K. Kurdistani,
University of California, Los Angeles, USA
Short Talk: Regulation of Intracellular pH by Histone Acetylation
Short Talk: Regulation of Intracellular pH by Histone Acetylation
Alejandro Vaquero,
Bellvitge Institute for Biomedical Research, Spain
Short Talk: SirT2 Regulates Cell Cycle Progression and Genome Stability by Modulating Mitotic Deposition of H4K20 Methylation
Short Talk: SirT2 Regulates Cell Cycle Progression and Genome Stability by Modulating Mitotic Deposition of H4K20 Methylation
14:30—16:30
Workshop 1
*
Mary Ann Osley,
University of New Mexico School of Medicine, USA
Masami Horikoshi,
University of Tokyo, Japan
“Modification Web” and “Signal Router” Theories on Histone Modification System and their Application to Development of Cancer Drugs
“Modification Web” and “Signal Router” Theories on Histone Modification System and their Application to Development of Cancer Drugs
Cigall Kadoch,
Dana-Farber Cancer Institute, Harvard Medical School, USA
Reversible Disruption of mSWI/SNF-Like BAF Complexes by the SS18-SSX Oncogenic Fusion in Synovial Sarcoma
Reversible Disruption of mSWI/SNF-Like BAF Complexes by the SS18-SSX Oncogenic Fusion in Synovial Sarcoma
Gary Hon,
University of Texas Southwestern Medical Center, USA
Whole Genome Bisulfite Sequencing Reveals Tissue-Specific DNA Methylation in a Normal Mouse
Whole Genome Bisulfite Sequencing Reveals Tissue-Specific DNA Methylation in a Normal Mouse
Tal H. Salz,
Johns Hopkins University, USA
hSET1 Regulates the Canonical Wnt-Signaling Pathway and Plays a Role in Colorectal Cancer
hSET1 Regulates the Canonical Wnt-Signaling Pathway and Plays a Role in Colorectal Cancer
Eleni Maniati,
Queen Mary University of London, UK
Functional Effect of Aberrant Mll2/3 Gene Expression in Pancreatic Cancer
Functional Effect of Aberrant Mll2/3 Gene Expression in Pancreatic Cancer
Cheng-Fu Kao,
Academia Sinica, Taiwan
H2B Monoubiquitylation Regulates the Replication Stress Response
H2B Monoubiquitylation Regulates the Replication Stress Response
17:00—19:00
Chromosomes, Chromatin and Transcription II
Richard A. Young,
Whitehead Institute for Biomedical Research, USA
Connecting Transcription, Chromatin and Cancer
Connecting Transcription, Chromatin and Cancer
Shiv I. S. Grewal,
NCI, National Institutes of Health, USA
Epigenetic Genome Control by RNAi and Heterochromatin Proteins
Epigenetic Genome Control by RNAi and Heterochromatin Proteins
Anne Schaefer,
Mount Sinai School of Medicine, USA
Short Talk: PRC2 is Essential for Adult Brain Function
Short Talk: PRC2 is Essential for Adult Brain Function
Johnathan R. Whetstine,
Fox Chase Cancer Center, USA
Short Talk: Looking at Cancer through the Eyes of Histone Demethylases
Short Talk: Looking at Cancer through the Eyes of Histone Demethylases
Charles Lin,
Baylor College of Medicine, USA
Short Talk: Transcription Amplification in Tumor Cells with Elevated c-Myc
Short Talk: Transcription Amplification in Tumor Cells with Elevated c-Myc
08:00—11:00
Polycomb and Trithorax in Gene Expression and Cancer
*
Shiv I. S. Grewal,
NCI, National Institutes of Health, USA
Ali Shilatifard,
Northwestern University, USA
Chromatin Modifications, Transcriptional Elongation Control and Childhood Leukemia
Chromatin Modifications, Transcriptional Elongation Control and Childhood Leukemia
Danny F. Reinberg,
HHMI/New York University, USA
PRC1 in Drosophila and Mammals
PRC1 in Drosophila and Mammals
Jürg Müller,
Max Planck Institute of Biochemistry, Germany
Molecular Mechanisms of the Polycomb System
Molecular Mechanisms of the Polycomb System
Peter Verrijzer,
Erasmus University Medical Center, Netherlands
Antagonism between Polycomb and Trithorax in Development and Disease
Antagonism between Polycomb and Trithorax in Development and Disease
Kami Ahmad,
Harvard Medical School, USA
Short Talk: The Chromatin Configuration of Polycomb Response Elements (PREs) Define Epigenetic States
Short Talk: The Chromatin Configuration of Polycomb Response Elements (PREs) Define Epigenetic States
François Fuks,
Université Libre de Bruxelles, Belgium
Short Talk: Molecular Basis of Tets: In Search of their Protein Partners
Short Talk: Molecular Basis of Tets: In Search of their Protein Partners
Zhiguo Zhang,
Mayo Clinic, USA
Short Talk: Histone Modifications Regulate DNA Replication Coupled Nucleosome Assembly
Short Talk: Histone Modifications Regulate DNA Replication Coupled Nucleosome Assembly
17:00—19:00
Histone Marks in Development and Cancer
Thomas Jenuwein,
Max Planck Institute of Immunobiology and Epigenetics, Germany
Making and Breaking Heterochromatin
Making and Breaking Heterochromatin
Tony Kouzarides,
University of Cambridge, UK
Chromatin Modification Pathways and their Role in Cancer
Chromatin Modification Pathways and their Role in Cancer
Alexander Tarakhovsky,
Rockefeller University, USA
Signaling Control of Epigenetic Fitness
Signaling Control of Epigenetic Fitness
Mary Ann Osley,
University of New Mexico School of Medicine, USA
Short Talk: The Histone Modification Landscape of Quiescent Yeast Cells Formed during Chronological Aging
Short Talk: The Histone Modification Landscape of Quiescent Yeast Cells Formed during Chronological Aging
08:00—11:00
DNA Methylation in Development and Cancer
*
B. Franklin Pugh,
Pennsylvania State University, USA
Yi Zhang,
HHMI/Harvard Medical School, Children's Hospital Boston, USA
Role of Tet1-Mediated 5mC Oxidation in PGC Reprogramming and Meiosis
Role of Tet1-Mediated 5mC Oxidation in PGC Reprogramming and Meiosis
Peter A. Jones,
Van Andel Research Institute, USA
DNA Methylation and Cancer Therapy
DNA Methylation and Cancer Therapy
Jean-Pierre Issa,
Temple University School of Medicine, USA
Epigenetic Reprogramming as Cancer Therapy
Epigenetic Reprogramming as Cancer Therapy
Roger Greenberg,
University of Pennsylvania, USA
Short Talk: Acetylation Determines Double-Strand Break Repair Choice and Response to PARP Inhibition
Short Talk: Acetylation Determines Double-Strand Break Repair Choice and Response to PARP Inhibition
Gregory David,
New York University School of Medicine, USA
Short Talk: Epigenetic Regulation of Inflammation Modulates KRas-Driven Pancreatic Cancer Progression
Short Talk: Epigenetic Regulation of Inflammation Modulates KRas-Driven Pancreatic Cancer Progression
Diana Hargreaves,
Stanford University, USA
Short Talk: BAF Complexes Cooperate with Topoisomerase II alpha to Decatenate DNA
Short Talk: BAF Complexes Cooperate with Topoisomerase II alpha to Decatenate DNA
Li-Jung Juan,
Academia Sinica, Taiwan
Short Talk: Mechanisms of DNA Demethylation Enzymes TET Family Proteins in Suppressing Tumor Malignancy
Short Talk: Mechanisms of DNA Demethylation Enzymes TET Family Proteins in Suppressing Tumor Malignancy
17:00—19:00
Enhancers and ncRNAs in Development and Cancer
*
Peter Verrijzer,
Erasmus University Medical Center, Netherlands
Jeannie T. Lee,
Massachusetts General Hospital / Harvard Medical School, USA
Xist RNA in the Establishment and Maintenance of X Chromosome Inactivation
Xist RNA in the Establishment and Maintenance of X Chromosome Inactivation
Robert A. Martienssen,
Cold Spring Harbor Laboratory, USA
Inheritance and Reprogramming of Heterochromatin with Small RNA
Inheritance and Reprogramming of Heterochromatin with Small RNA
Celso A. Espinoza,
AbbVie Inc., USA
Short Talk: Architectural Studies of Intramolecular Interactions between Enhancers and Promoters via ChIP-HiC
Short Talk: Architectural Studies of Intramolecular Interactions between Enhancers and Promoters via ChIP-HiC
08:00—11:00
Myc, Transcriptional Regulation and Development
*
Kapil N. Bhalla,
MD Anderson Cancer Center, USA
Robert N. Eisenman,
Fred Hutchinson Cancer Research Center, USA
Cooperative Transcriptional Regulation of Metabolism Mediated by the Myc-Max/MondoA-Mlx Network
Cooperative Transcriptional Regulation of Metabolism Mediated by the Myc-Max/MondoA-Mlx Network
Michael D. Cole,
Dartmouth Medical School, USA
An Epigenetic Model for Myc Autoregulation and Gene Repression
An Epigenetic Model for Myc Autoregulation and Gene Repression
Bruno Amati,
Italian Institute of Technology and European Institute of Oncology, Italy
Epigenome and Transcriptome Regulation in Myc-Driven Tumors
Epigenome and Transcriptome Regulation in Myc-Driven Tumors
James E. Bradner,
Novartis Institutes for BioMedical Research, USA
Targeting Gene Regulatory Pathways
Targeting Gene Regulatory Pathways
Lin-Feng Chen,
University of Illinois at Urbana-Champaign, USA
Short Talk: Brd4 Maintains Constitutively Active NF-kappaB in Cancer Cells by Binding to Acetylated RelA
Short Talk: Brd4 Maintains Constitutively Active NF-kappaB in Cancer Cells by Binding to Acetylated RelA
Junwei Shi,
Cold Spring Harbor Laboratory, USA
Short Talk: Collaboration between the BAF Complex and Brd4 Maintains Myc Expression in Leukemia
Short Talk: Collaboration between the BAF Complex and Brd4 Maintains Myc Expression in Leukemia
Katherine A. Jones,
The Salk Institute, USA
Short Talk: Beta-Catenin Ubiquitylation and Release from LEF-1/TCF by a Novel alpha-Catenin:APC Complex
Short Talk: Beta-Catenin Ubiquitylation and Release from LEF-1/TCF by a Novel alpha-Catenin:APC Complex
14:30—16:30
Workshop 2
*
Roger Greenberg,
University of Pennsylvania, USA
Klaas Kok,
University Medical Center Groningen, Netherlands
The Impact of SETD2-Inactivating Mutations and Loss of H3K36 Trimethylation on Gene Expression in Clear Cell Renal Cell Carcinoma Progenitor Cells
The Impact of SETD2-Inactivating Mutations and Loss of H3K36 Trimethylation on Gene Expression in Clear Cell Renal Cell Carcinoma Progenitor Cells
Hao A. Duong,
Harvard Medical School, USA
Temporal Coordination of Histone De-Acetylase and Methyl-Transferase in Circadian Transcriptional Repression
Temporal Coordination of Histone De-Acetylase and Methyl-Transferase in Circadian Transcriptional Repression
Seung Hyuk Choi,
The Salk Institute, USA
Role for alpha-Catenin in APC-Mediated Repression at Wnt Target Genes
Role for alpha-Catenin in APC-Mediated Repression at Wnt Target Genes
Emily A. Clough,
NIDDK, National Institutes of Health, USA
The H4K16 Histone Acetyltransferase Chameau Is a Putative Target of Doublesex
The H4K16 Histone Acetyltransferase Chameau Is a Putative Target of Doublesex
Anil K. Panigrahi,
Baylor College of Medicine, USA
Dissecting the Role of H3K79 Methylation in Transcription Elongation and Leukemia
Dissecting the Role of H3K79 Methylation in Transcription Elongation and Leukemia
17:00—19:15
Transcription, Chromatin and Epigenetics in Cancer Therapy
*
Robert N. Eisenman,
Fred Hutchinson Cancer Research Center, USA
Laurie A. Boyer,
Massachusetts Institute of Technology, USA
Developmental Transitions in Heart Development
Developmental Transitions in Heart Development
Robert J. Gould,
Fulcrum Therapeutics, USA
Drugging the Human Methylome: Discovery and Characterization of Inhibitors of Protein Methyltransferases for the Treatment of Genetically Defined Cancers
Drugging the Human Methylome: Discovery and Characterization of Inhibitors of Protein Methyltransferases for the Treatment of Genetically Defined Cancers
Patrick Trojer,
Constellation Pharmaceuticals, USA
Targeting Histone Lysine Methylation in Cancer
Targeting Histone Lysine Methylation in Cancer
Marie Classon,
, USA
Short Talk: Chromatin Modifications and the Establishment of Drug-Tolerance
Short Talk: Chromatin Modifications and the Establishment of Drug-Tolerance
Kapil N. Bhalla,
MD Anderson Cancer Center, USA
Short Talk: Highly Effective Combination of LSD1 Antagonist SP-2509 and Pan-HDAC Inhibitor Against Human AML Cells
Short Talk: Highly Effective Combination of LSD1 Antagonist SP-2509 and Pan-HDAC Inhibitor Against Human AML Cells
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
|
|
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
|
|
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
